Liquid Biopsies for Cancer.

What is liquid biopsy?

Liquid biopsy refers to blood-based detection of tumor-derived analytes—primarily circulating tumor DNA (ctDNA)—used to identify actionable mutations, monitor treatment response, and detect minimal residual disease (MRD).

Liquid Biopsy Is Rewriting the Future of Cancer Diagnostics — Here’s What Matters for IVD Strategy.

Liquid biopsy has moved from scientific promise to clinical reality—and the latest JAMA[1] review makes one thing clear: ctDNA-based testing is becoming indispensable across oncology care pathways. For diagnostics companies, investors, and clinical laboratories, this shift represents one of the most consequential market transformations in the last decade.

Why is ctDNA winning?

Traditional tissue biopsy remains essential, but it cannot match the speed, repeatability, and molecular resolution of ctDNA analysis. As cancer becomes increasingly treated through targeted and adaptive therapies, clinicians need tools that detect molecular change before radiographic progression. Liquid biopsy delivers exactly that.

Evidence that changes the market. Three high-impact studies highlighted in JAMA illustrate how ctDNA is reshaping clinical decision-making:

• KRAS G12C NSCLC: ctDNA enables rapid identification of patients eligible for targeted therapy, supporting the commercial rise of mutation-specific companion diagnostics.

• ESR1 mutant breast cancer: Serial ctDNA monitoring allows therapy switches months earlier than imaging—creating demand for longitudinal testing models and subscription-based lab partnerships.

• Colorectal cancer MRD: ctDNA positivity predicts recurrence with 10–12× higher risk, accelerating adoption of MRD assays in postoperative surveillance programs.

These findings are not just clinically meaningful—they are commercially catalytic.

What does this mean for diagnostic manufacturers?

The market is shifting toward continuous molecular monitoring, not one-time testing. Companies that succeed will:

• Build high-sensitivity MRD platforms with validated recurrence risk algorithms.

• Offer rapid turnaround ctDNA panels for therapy selection.

• Integrate longitudinal testing workflows into oncology practices and health systems.

• Demonstrate clinical utility through real-world evidence and guideline-aligned studies.

Liquid biopsy is no longer the future—it’s the present. If your organization is building, acquiring, or commercializing ctDNA-based diagnostics, now is the time to move.

Reach out to GRN IVD Consulting to accelerate your strategy in the rapidly expanding liquid biopsy market.